查詢結果分析
相關文獻
- 治療晚期非小細胞肺癌的表皮生長因子受體-酪胺酸激酶抑制劑
- 抗血管新生治療於非小細胞肺癌之應用
- 晚期非小細胞肺癌的個人化治療
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)-Related Severe Interstitial Lung Disease in Taiwanese Patients with Non-Small Cell Lung Cancer
- Outcomes of Mechanically Ventilated Non-Small Cell Lung Cancer Patients Receiving Tyrosine Kinase Inhibitors in Intensive Care Units
- EGFR-TKIs用於晚期非小細胞肺癌
- Newly Developing Osteoblastic Lesions during Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Do Not Necessarily Indicate Disease Progression
- 進展性非小細胞肺癌之病例用藥探討
- 非小細胞肺癌的標靶治療
- 表皮生長因子受體-酪氨酸激酶抑制劑所導致之間質性肺疾病
頁籤選單縮合
題名 | 治療晚期非小細胞肺癌的表皮生長因子受體-酪胺酸激酶抑制劑=Treatment with EGFR-TK Inhibitor for Advanced Non-small Cell Lung Cancer |
---|---|
作者姓名(中文) | 吳秋玫; 曾美容; | 書刊名 | 藥學雜誌 |
卷期 | 26:4=105 2010.12[民99.12] |
頁次 | 頁52-57 |
分類號 | 418.31 |
關鍵詞 | 表皮生長因子受體; 酪胺酸激酶抑制劑; 非小細胞肺癌; Erlotinib; EGFR-TK inhibitor; NSCLC gefitinib; |
語文 | 中文(Chinese) |
中文摘要 | 許多歐美先進國家與台灣一樣,肺癌的發生率及死亡率皆高居首位。對於轉移性或已經經歷化療又復發的末期非小細胞肺癌,在治療上是個棘手的問題。不過現在有更多的臨床研究,證實小分子表皮生長因子受體 -酪胺酸激酶抑制劑,如 erlotinib、 gefitinib等可作為第一線化療失敗後的第二線治療藥,它們可增加病人存活率及提高生活品質,然而,抗藥性卻是其治療失敗的隱憂。對於目前研發的多標靶藥物,如 vandetanib、XL 647、BIBW 2992等,它們能帶給病患多少益處還需更多、更長期及大規模的臨床試驗加以證實。 |
英文摘要 | The prevalence and motality rate for lung cancer in Taiwan are very similar with most developed countries in Europe and America. It is very difficult to treat patients on non-small cell lung cancer after metastatic or relapsed from initial chemotherapy. Yet many subsequent clinical studies have demonstrated the success of using small molecule epidermal growth factor receptor -tyrosine kinase inhibitors such as erlotinib, gefitinib to be the second-line treatment if the first-line chemotherapy failed to improve their survival and quality of life.However, we worry about that resistance leads to failure in treatment. Currently, the benefit of multi-targeted drugs such as vandetanib, XL 647 and BIBW 2992 will need to be further proved by applying to larger scale of clinical tests with longer duration. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。